Literature DB >> 2039366

Liver viability after ischemia-reperfusion.

A A Rodriguez1, W W LaMorte, L M Hanrahan, S R Hopkins, J C O'Keane, R Cachecho, E F Hirsch.   

Abstract

Lack of a reproducible model to quantitatively assess hepatocellular injury following ischemia has made it difficult to assess new strategies for minimizing hepatic injury. We studied the progression of hepatocellular injury after ischemia and ischemia with reperfusion in rats. Irreversible injury was quantitated using a triphenyltetrazolium chloride assay that was shown to correlate with ultrastructural changes. Adenosine triphosphate decreased to 36% of basal values after 30 minutes, but returned to normal with reperfusion with no decrease in viability. In contrast, viability fell by 30% after 60 minutes of ischemia, and by 64% when 60 minutes of ischemia was followed by reperfusion. We conclude that reperfusion of ischemic liver increases the degree of irreversible damage. The model employed here seems to be useful for studying ischemic and reperfusion injury in the liver.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039366     DOI: 10.1001/archsurg.1991.01410300113018

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Safe upper limit of intermittent hepatic inflow occlusion for liver resection in cirrhotic rats.

Authors:  D X Lei; C H Peng; S Y Peng; X C Jiang; Y L Wu; H W Shen
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  "Varicoid change" of bile canaliculi in rat liver at an early phase of ischaemia-reperfusion injury.

Authors:  H Yasui; T Takamatsu; S Fujita
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

3.  Morphological alterations and redox changes associated with hepatic warm ischemia-reperfusion injury.

Authors:  Rim Jawad; Melroy D'souza; Lisa Arodin Selenius; Marita Wallenberg Lundgren; Olof Danielsson; Greg Nowak; Mikael Björnstedt; Bengt Isaksson
Journal:  World J Hepatol       Date:  2017-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.